Johnson & Johnson
NYSE:JNJ

Watchlist Manager
Johnson & Johnson Logo
Johnson & Johnson
NYSE:JNJ
Watchlist
Price: 202.48 USD -1.39% Market Closed
Market Cap: 487.8B USD

Intrinsic Value

The intrinsic value of one JNJ stock under the Base Case scenario is 173.28 USD. Compared to the current market price of 202.48 USD, Johnson & Johnson is Overvalued by 14%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

JNJ Intrinsic Value
173.28 USD
Overvaluation 14%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Johnson & Johnson

What is Valuation History?
Ask AI Assistant
What other research platforms think about JNJ?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is JNJ valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Johnson & Johnson.

Explain Valuation
Compare JNJ to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Continued legal challenges, especially around talc-based products and opioid-related lawsuits, could result in substantial settlement costs and negatively impact Johnson & Johnson’s reputation and cash flow.

The recent consumer health spinoff (Kenvue) could dilute brand synergies and disrupt revenue diversification, hindering Johnson & Johnson’s ability to leverage cross-segment strengths in marketing and R&D.

Potential patent expirations in the pharmaceutical segment and intensifying generic competition may reduce pricing power, forcing Johnson & Johnson to allocate additional resources to pipeline development and acquisitions.

Bull Theses

Its diversified portfolio across pharmaceuticals, medical devices, and consumer health products insulates Johnson & Johnson from downturns in any single category, supporting stable revenue and cash generation.

Robust late-stage pharmaceutical pipeline, particularly in oncology and immunology, could secure new growth avenues and help counterbalance upcoming patent expirations.

The spinoff of Kenvue may allow Johnson & Johnson to focus on higher-margin segments, such as medical devices and pharmaceuticals, improving profitability and operational efficiency over the long term.

Show More Less
How do you feel about JNJ?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Johnson & Johnson

Current Assets 54.6B
Cash & Short-Term Investments 18.6B
Receivables 17.6B
Other Current Assets 18.4B
Non-Current Assets 138.2B
Long-Term Investments 573m
PP&E 22.3B
Intangibles 96.8B
Other Non-Current Assets 18.5B
Current Liabilities 50.9B
Accounts Payable 9.6B
Accrued Liabilities 32.9B
Short-Term Debt 4.4B
Other Current Liabilities 3.9B
Non-Current Liabilities 62.7B
Long-Term Debt 39.4B
Other Non-Current Liabilities 23.3B
Efficiency

Free Cash Flow Analysis
Johnson & Johnson

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Johnson & Johnson

Revenue
92.1B USD
Cost of Revenue
-29.4B USD
Gross Profit
62.8B USD
Operating Expenses
-37.9B USD
Operating Income
24.9B USD
Other Expenses
242m USD
Net Income
25.1B USD
Fundamental Scores

JNJ Profitability Score
Profitability Due Diligence

Johnson & Johnson's profitability score is 63/100. The higher the profitability score, the more profitable the company is.

Exceptional 3Y Average ROE
Exceptional ROE
Exceptional Gross Margin
Healthy Operating Margin
63/100
Profitability
Score

Johnson & Johnson's profitability score is 63/100. The higher the profitability score, the more profitable the company is.

JNJ Solvency Score
Solvency Due Diligence

Johnson & Johnson's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Long-Term Solvency
Short-Term Solvency
55/100
Solvency
Score

Johnson & Johnson's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

JNJ Price Targets Summary
Johnson & Johnson

Wall Street analysts forecast JNJ stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for JNJ is 205.15 USD with a low forecast of 171.7 USD and a high forecast of 241.5 USD.

Lowest
Price Target
171.7 USD
15% Downside
Average
Price Target
205.15 USD
1% Upside
Highest
Price Target
241.5 USD
19% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for JNJ is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

JNJ Insider Trading
Buy and sell transactions by insiders

JNJ News

Other Videos
What is the Intrinsic Value of one JNJ stock?

The intrinsic value of one JNJ stock under the Base Case scenario is 173.28 USD.

Is JNJ stock undervalued or overvalued?

Compared to the current market price of 202.48 USD, Johnson & Johnson is Overvalued by 14%.

Back to Top